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Abstract: BACKGROUND The purpose of this study was to assess the impact of vendor-provided atlas-
based MRAC on FDG PET/MR for the evaluation of Alzheimer’s disease (AD) by using simulated images.
METHODS We recruited 47 patients, from two institutions, who underwent PET/CT and PET/MR
(GE SIGNA) examination for oncological staging. From the PET raw data acquired on PET/MR, two
FDG-PET series were generated, using vendor-provided MRAC (atlas-based) and CTAC. The following
simulation steps were performed in MNI space: After spatial normalization and smoothing of the PET
datasets, we calculated the error map for each patient, PETMRAC/PETCTAC. We multiplied each of
these 47 error maps with each of the 203 Alzheimer’s Disease Neuroimaging Initiative (ADNI) cases
after the identical normalization and smoothing. This resulted in 203*47 = 9541 datasets. To evaluate
the probability of AD in each resulting image, a cumulative t-value was calculated automatically using
commercially-available software (PMOD PALZ) which has been used in multiple large cohort studies.
The diagnostic accuracy for the discrimination of AD and predicting progression from mild cognitive
impairment (MCI) to AD were evaluated in simulated images compared with ADNI original images.
RESULTS The accuracy and specificity for the discrimination of AD-patients from normal controls were
not substantially impaired, but sensitivity was slightly impaired in 5 out of 47 datasets (original vs.
error; 83.2% [CI 75.0%-89.0%], 83.3% [CI 74.2%-89.8%] and 83.1% [CI 75.6%-88.3%] vs. 82.7% [range
80.4-85.0%], 78.5% [range 72.9-83.3%,] and 86.1% [range 81.4-89.8%]). The accuracy, sensitivity and
specificity for predicting progression from MCI to AD during 2-year follow-up was not impaired (original
vs. error; 62.5% [CI 53.3%-69.3%], 78.8% [CI 65.4%-88.6%] and 54.0% [CI 47.0%-69.1%] vs. 64.8% [range
61.5-66.7%], 75.7% [range 66.7-81.8%,] and 59.0% [range 50.8-63.5%]). The worst 3 error maps show a
tendency towards underestimation of PET scores. CONCLUSION FDG-PET/MR based on atlas-based
MR attenuation correction showed similar diagnostic accuracy to the CT-based method for the diagnosis
of AD and the prediction of progression of MCI to AD using commercially-available software, although
with a minor reduction in sensitivity.
DOI: https://doi.org/10.1371/journal.pone.0233886
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The purpose of this study was to assess the impact of vendor-provided atlas-based MRAC
on FDG PET/MR for the evaluation of Alzheimer’s disease (AD) by using simulated images.
Methods
We recruited 47 patients, from two institutions, who underwent PET/CT and PET/MR (GE
SIGNA) examination for oncological staging. From the PET raw data acquired on PET/MR,
two FDG-PET series were generated, using vendor-provided MRAC (atlas-based) and
CTAC. The following simulation steps were performed in MNI space: After spatial normaliza-
tion and smoothing of the PET datasets, we calculated the error map for each patient, PETM-
RAC/PETCTAC. We multiplied each of these 47 error maps with each of the 203 Alzheimer’s
Disease Neuroimaging Initiative (ADNI) cases after the identical normalization and smooth-
ing. This resulted in 203*47 = 9541 datasets. To evaluate the probability of AD in each
resulting image, a cumulative t-value was calculated automatically using commercially-
available software (PMOD PALZ) which has been used in multiple large cohort studies. The
diagnostic accuracy for the discrimination of AD and predicting progression frommild cogni-
tive impairment (MCI) to AD were evaluated in simulated images compared with ADNI origi-
nal images.
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Results
The accuracy and specificity for the discrimination of AD-patients from normal controls were
not substantially impaired, but sensitivity was slightly impaired in 5 out of 47 datasets (origi-
nal vs. error; 83.2% [CI 75.0%-89.0%], 83.3% [CI 74.2%-89.8%] and 83.1% [CI 75.6%-
88.3%] vs. 82.7% [range 80.4–85.0%], 78.5% [range 72.9–83.3%,] and 86.1% [range 81.4–
89.8%]). The accuracy, sensitivity and specificity for predicting progression fromMCI to AD
during 2-year follow-up was not impaired (original vs. error; 62.5% [CI 53.3%-69.3%], 78.8%
[CI 65.4%-88.6%] and 54.0% [CI 47.0%-69.1%] vs. 64.8% [range 61.5–66.7%], 75.7%
[range 66.7–81.8%,] and 59.0% [range 50.8–63.5%]). The worst 3 error maps show a ten-
dency towards underestimation of PET scores.
Conclusion
FDG-PET/MR based on atlas-based MR attenuation correction showed similar diagnostic
accuracy to the CT-based method for the diagnosis of AD and the prediction of progression
of MCI to AD using commercially-available software, although with a minor reduction in
sensitivity.
Background
Integrated positron emission tomography (PET) / magnetic resonance (MR) systems have
been currently widely distributed (over 100 institutions in the world). Previous studies have
revealed that 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-PET/MR is useful in the evaluation of
neurodegenerative diseases [1–6]. Additionally, combined PET/MR not only provides detailed
brain anatomy, but the immediate availability of coregistered anatomy might even improve
PET image quality by facilitating the correction of partial volume effects and/or motion arti-
facts [7, 8]. However, several technical challenges should be solved to exploit the full perfor-
mance of PET/MR. One of the limitations in need of improvement is that of attenuation
correction (AC) using MR imaging data (MRAC) [9]. On PET/MR system, it is difficult to
derive AC-maps from conventional MR-data due to the lack of a relationship between photon
attenuation and MR signal intensity. To solve this problem, several AC-methods (i.e. Dixon-
based AC, Atlas-based AC, Model-based AC, zero echo time MRI based AC and ultrashort
echo time MRI based AC) have been proposed from vendors and researchers [9, 10]. For clini-
cal use, Dixon-based four-class segmentation approaches (i.e. air, lung, fat and soft tissue) was
implemented into both the Biograph mMR (Siemens Healthcare, Erlangen, Germany) and
SIGNA PET/MR (GE Healthcare, Waukesha, WI, USA). However, these methods are not rec-
ommended for brain studies, because neglecting bone introduces a significant bias in cortical
areas [11]. One of the alternative methods currently implemented on clinical PET/MR scan-
ners is the atlas-based method [12, 13]. This method is comparably accurate in supratentorial
regions, but not accurate enough in the temporal lobe and in the infratentorial region, where
FDG uptake is underestimated. This variability of error distribution may impact the diagnostic
accuracy of FDG PET in several diseases, including Alzheimer’s disease (AD). Quantitative
evaluation of FDG-PET typically relies on a normalization of local FDG uptake to that in dedi-
cated anatomical regions (e.g. cerebellum and thalamus) or to the whole brain average. If the
regions with overestimated FDG accumulation are normalized to an underestimated region,
or vice versa, the result could be under- or over-diagnosis of AD. However, the impact of the
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The aim of this paper was to clarify the clinical utility of FDG-PET from PET/MR, with
vendor-provided atlas-based MRAC, for the diagnosis of AD. The analysis was performed on
simulated data that combined real patient data from two institutions (Institution A (InA) and
B (InB)) and Alzheimer Disease Neuroimaging Initiative (ADNI) data, well-established large
cohort data. The probability of AD was calculated using fully automated procedures in com-
mercially available software.
Materials andmethods
This study was approved by each local institutional review board, cantonal ethics committee
Zurich and Institutional Review Board of Mayo Clinic. All subjects provided signed informed
consent prior to the examinations. All experiments were performed in accordance with rele-
vant guidelines and regulations. We recruited 47 patients, from two institutions, who under-
went both PET/CT and PET/MR (GE SIGNA) examination. In addition, we extracted 203
subjects from the ADNI dataset. From the PET raw data acquired on PET/MR, two FDG-PET
series were generated, using either the vendor-provided atlas-based MRAC or CTAC. Follow-
ing spatial normalization to MNI space, we calculated the error map for each patient, as PETM-
RAC/PETCTAC. We multiplied each of these 47 error maps with each of the 203 ADNI cases in
MNI space. This resulted in 203�47 = 9541 datasets (Fig 1). To evaluate the probability of AD
in each resulting image, a cumulative t-value was calculated using a fully automated method in
commercially-available software (S1 Fig). The diagnostic accuracy for the discrimination of
AD and predicting progression from mild cognitive impairment (MCI) to AD were evaluated
in simulated images compared with the original ADNI images (Fig 1).
Alzheimer Disease Neuroimaging Initiative (ADNI) data
Data used in the preparation of this article were obtained from the ADNI database (adni.loni.
usc.edu). ADNI was launched in 2003 as a public-private partnership, led by Principal Investi-
gator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial mag-
netic resonance imaging (MRI), positron emission tomography (PET), other biological
markers, and clinical and neuropsychological assessment can be combined to measure the pro-
gression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). For up-to-
date information, see www.adni-info.org. The authors had no special access privileges to the
data others would not have. It means that any interested researchers can replicate the current
study findings in their entirety by directly obtaining the data from ADNI’s website and com-
bining their own error map dataset.
From ADNI-1 data, we extracted 203 participants (76.0±6.3 years, 129 males, 48 healthy, 59
AD and 96 MCI participants). Out of 96 MCI participants, 33 progressed to AD at 24 months
after imaging. The inclusion criteria were: completeness of date of birth, baseline diagnosis
(healthy, MCI, or AD) and the diagnosis at 24 months after imaging. All PET images were of
sufficient quality for visual scoring and for software-based analysis using PMOD’s Alzheimer
Discrimination tool PALZ (PMOD Technologies LLC, Zurich, Switzerland) [14, 15]. The base-
line PET data was utilized. The reported FDG-PET imaging parameters were: injected dose,
185 MBq (5 mCi), dynamic 3D acquisition, six 5-min frames 30–60 min post injection.
Patients
We recruited 47 patients who underwent both PET/CT and PET/MR for oncologic staging
from two institutions (InA and InB). Twenty patients (11 males and 9 females, 61.6±12.4
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years) with lymphoma, lung cancer, head and neck cancer, pancreatic cancer, pleural methote-
lioma, uterine carcinoma, cervical carcinoma and malignant melanoma at InA were collected
by summing the cohorts recruited in previous studies [12, 16]. The other twenty-seven patients
(15 males and 12 females, 60.0±13.0 years) with lymphoma, pheochromocytoma, myeloma,
melanoma, Merker-cell cancer, lung cancer, pancreatic cancer, breast cancer and dementia at
InB were collected from another previous study, after excluding 3 patients. Two of these three
excluded patients had infarction and one had multiple brain metastases [17]. A neuroradiolo-
gist (T.S.) reviewed and confirmed that all included patients were free of brain abnormalities.
PET/CT and PET/MR acquisition
The averaged injected dose of FDG was 233.2±42.1MBq (range, 179.4–325.7 MBq) at InA and
534±42 MBq [range, 434–566 MBq] at InB. The PET/CT acquisition followed the standard
protocol for a clinical oncology study. InA used a Discovery 690 PET/CT (GE Healthcare) and
Fig 1. Summarized workflow used to generate the simulated PET dataset with error derived fromMRAC. A detailed description of the procedure is provided in the
materials and methods section.
https://doi.org/10.1371/journal.pone.0233886.g001
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InB used a Discovery RX/MI/690/710 PET/CT (GE Healthcare). A helical whole-body CT
scan (120 kV, slice thickness 3.3mm, pixel dimensions 1.4×1.4 mm2 at InA and 120–140 kV,
slice thickness 3.75–5.00 mm, pixel size 1.37×1.37 mm2 at InB) was acquired for AC of PET
data and diagnostic purposes [18]. Subsequently, a whole-body PET dataset including the head
was acquired. Immediately before or after the PET/CT scan, patients were transferred to the
integrated PET/MR scanner (SIGNA PET/MR, GE Healthcare), and a brain PET/MR scan was
performed as part of the study examination. A 2 min PET acquisition at InA and a 10 min
acquisition at InB with a standard head coil (8-channnel HD Brain; GE Healthcare) was per-
formed. The duration between tracer injection and PET acquisition was 116±31 min [range,
48–183 min] at InA and 112±15 min [range, 66–138 min] at InB.
During the PET acquisition on the PET/MR, liver acquisition with volume acceleration flex
(LAVA-Flex) T1w images (axial acquisition, TR ~ 4 ms, TE 2.23 ms, flip angle 5˚, slice thick-
ness 5.2 mm with 2.6 mm overlap, 120 slices, pixel size 1.95 × 1.95 mm2, number of excitations
(NEX) 0.9, acquisition time: 18 s) were acquired for vendor-provided atlas-based AC [13].
Attenuation map generation
The atlas AC map was calculated from the LAVA-Flex T1w images using the vendor-provided
default processing [18].
For the generation of CTAC, the processing steps detailed below were performed using cus-
tomMatlab scripts and PMOD 3.8. The co-registered CTACmap was generated as follows.
First, the original head CT was exported from the PET/CT scanner and converted into an AC
map using a Matlab version of the same bilinear mapping implemented in the SIGNA PET/
MRI. From this map, the CT table was removed manually. A threshold was set to extract the
outside air component from the CTACmap. None of the images used in this study contained
artifacts likely to affect air thresholding. To derive the registration parameters necessary to
match CT to LAVA-Flex T1w, a normalized mutual information matching algorithm
(PMOD) was used and the final matching was performed using customMatlab routines.
Finally, the CTACmap was superimposed on the atlas AC map, replacing it [13].
Reconstruction of PET images
Only the list-mode raw PET data from the PET/MR examination were used. PET images were
reconstructed twice, using either atlas AC or silver-standard CTAC using the following param-
eters: InA, fully 3D ordered subset expectation maximization iterative reconstruction (OSEM),
subsets 28, iterations 8, pixel size 1.17 × 1.17 mm2, point spread function (PSF) modeling,
transaxial post-reconstruction Gaussian filter cutoff 3mm, axial filter 1:4:1, scatter, normaliza-
tion, dead-time and decay corrections, TOF reconstruction; InB, fully 3D OSEM, subsets 28,
iterations 3, pixel size 1.56 × 1.56 mm2, PSF modeling, transaxial post-reconstruction Gaussian
filter cutoff 3mm, axial filter 1:4:1, scatter, normalization, dead-time and decay corrections,
TOF reconstruction.
Automated software for AD probability assessment
Automated AD probability assessment was performed in a commercially available tool
(PMOD Alzheimer’s Discrimination, PALZ). This software tool has been used in multiple
large cohort studies, e.g. ADNI, NEST-DD and SEAD-Japan [15, 19, 20]. The software ran the
following procedures, in a fully automated workflow, in accordance to the methods described
by Herholz et al. [21]. First, spatial normalization is performed by transforming the original
images to the SPM99 PET template, followed by smoothing with a Gaussian filter of 12 x 12 x
12 mm [22, 23]. In these images, voxel values are normalized by dividing each image voxel
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value by the mean voxel value, averaged within a mask representing voxels in which FDG
uptake is typically preserved even in AD patients. The expected value in each voxel is calcu-
lated from a pre-stored, age-matched, reference PET database of healthy controls. This is
achieved by combining voxel-wise regression parameters, where brain atrophy was taken into
account by adjustment of the normal reference values using linear regression by age. By com-
paring the voxel-wise differences between expected value and the patient-specific value, a Stu-
dent’s t-value is calculated [24]. The AD t-sum is calculated by summing the t-value in
predefined AD-related voxels. Finally, the PET Score was calculated as log2 (AD t-sum/11089
+1), for which the 95% prediction limit (11089) of AD t-sum was established in the NEST-DD
multi-center trial [15]. This analysis was initially performed in all 203 ADNI-PET data (e.g.
PETScoreADNI−j) before multiplication with the 47 error maps. The detailed procedure is
shown in S1 Fig.
Creation of simulated data: ADNI-data with Atlas-AC
All simulation steps were performed in MNI space with same spatial resolution (2 mm isotro-
pic voxels). First, we divided the locally acquired PET images based on atlas AC by those based
on CTAC (47 patients) (e.g. ErrorPET
pt−i). Second, the resulting images were spatially normal-
ized to the SPM99 PET template using the transformation calculated for PET images based on
CTAC to the template, then a Gaussian filter of 12 x 12 x 12 mm full-width half-maximum was
applied (NormError PET
pt i). A brain mask was applied to avoid distortion at the edges of the mea-
sured data. These steps were designed to replicate the preprocessing steps used in the PMOD
Alzheimer’s Discrimination tool, as used to calculate PET score. Therefore, the resulting
images were the error maps (between atlas AC and CTAC) in the same image space as the spa-
tially normalized ADNI PET data (NormPETADNI−j). Third, we multiplied each of the 203 nor-
malized ADNI data with each of the 47 normalized error maps, resulting in 203�47 = 9541
normalized PET images (e.g. NormError PET
pt i
ADNI j). Thus, the value-error was simply imposed in a
voxel-wise manner and further PET score calculation was performed without additional need
for spatial deformation or filtering. Therefore, we expected any bias due to impaired spatial
normalization or differences in PET acquisition protocol to be minimized. For each of these
9541 images, PALZ analysis (from the second to fifth analysis step) was performed to calculate
the PET score (PETScore
pt i
ADNI j). This workflow is summarized in Fig 1.
Evaluation of diagnostic accuracy for Alzheimer’s disease
First, to clarify the distribution of MRAC error, we calculated the averaged error in whole
SPM 99 PET voxels, whole AD-related voxels and whole non-AD related voxels in each of the
47 normalized error map ð
Norm
Error PET
pt iÞ. Second, we calculated the difference in PET score
(PETScore
pt i
ADNI j PETScoreADNI j) for all 9541 datasets. To reveal whether differing PET acqui-
sition protocols affected the simulation results, we additionally compared PET score between
InA and InB.
We evaluated the diagnostic accuracy from two points of view. First was the diagnostic
accuracy of discrimination of AD from normal patients. Based on a previous study, the cut-off
is PET score = 1 [15]. Second was the diagnostic accuracy of prediction of conversion from
MCI to AD [14]. For the prediction fromMCI to AD, the PET score cut-off is 0.79, defined
using the Youden index [25].
We calculated sensitivity and specificity using the data for each error map multiplied by
each PET image. We created Bland-Altman plots of PET scores in the best 3 and the worst 3
cases [26]. The confidence intervals (CI) were calculated using the original data.
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Results
In 47 normalized error map, whole voxels of SPM 99 were slightly underestimated (-1.37%
±1.98%). In detail, AD-related voxels were less underestimated than non AD-related voxels
(-0.86%±2.03% vs. -1.59%±1.98%). As a result, compared with the reference PET score derived
from original 203 ADNI data, the PET score from 9541 simulated data was slightly underesti-
mated (-0.068±0.046). There was no statistical difference in PET score between the patient
groups from InA and InB (-0.070±0.045 vs. -0.066±0.046; p = 0.392).
Neither accuracy nor specificity for the discrimination of AD patients from normal controls
were significantly impaired by MRAC, but sensitivity was slightly impaired when using 5 out
of 47 error maps (original vs. error; 83.2% [CI 75.0%-89.0%], 83.3% [CI 74.2%-89.8%] and
83.1% [CI 75.6%-88.3%] vs. 82.7% [range 80.4–85.0%], 78.5% [range 72.9–83.3%,] and 86.1%
[range 81.4–89.8%]) (Table 1 and Fig 2A).
The accuracy, sensitivity, or specificity for predicting progression fromMCI to AD during
2-year follow-up were maintained by MRAC (62.5% [CI 53.3%-69.3%], 78.8% [CI 65.4%-
88.6%] and 54.0% [CI 47.0%-69.1%] vs. 64.8% [range 61.5–66.7%], 75.7% [range 66.7–81.8%,]
and 59.0% [range 50.8–63.5%]) (Table 1 and Fig 2B). The worst 3 error maps showed a ten-
dency towards underestimation of PET scores (Fig 3). A representative case is shown in Fig 4.
Discussion
In the current study, we estimated the diagnostic accuracy of FDG-PET with vendor-provided
atlas AC from PET/MR (GE SIGNA) for AD. This was achieved by simulating the error intro-
duced by MRAC on ADNI data and investigating the subsequent effect on an automated
method for Alzheimer’s discrimination. The result shows that error induced by MRAC could
lead to an underestimation of the probability of AD. Accuracy and specificity were maintained,
but sensitivity for the discrimination of Alzheimer’s disease from normal subjects was slightly
impaired. A similar slight tendency was found for the prediction of progression fromMCI to
AD.
There have been few studies evaluating diagnostic accuracy for AD in clinical PET/MR
machines that included more than 10 patients. Hitz et al. recruited 30 patients with suspected
AD [27]. FDG-PET imaging on PET/CT with CTAC and that on PET/MR with MRAC were
generated separately. Quantitative analysis showed that inconsistent over- and underestima-
tion, depending on the anatomical region, was apparent on PET/MR even after normalization
to the global mean. In visual assessment, even experienced observer ratings diverged between
PET/CT and PET/MR in 3 out of 29 patients. In this study, they used Dixon-based MRAC,
which is no longer recommended for use in brain PET/MR imaging, and generated PET data
Table 1. Diagnostic accuracy of original PET data and simulatedMRAC PET data.
Original MRAC (47 datasets)
Average Worst Best
Discrimination AD from normal Accuracy 83.2% (CI: 75.0–89.0%) 82.7% 80.4% 85.0%
Sensitivity 83.3% (CI: 74.2–89.8%) 78.5% 72.9% 83.3%
Specificity 83.1% (CI 75.6–88.3%) 86.1% 81.4% 89.8%
Prediction of progression fromMCI to AD Accuracy 62.5% (CI: 53.3–69.3%) 64.8% 61.5% 66.7%
Sensitivity 78.8% (CI: 65.4–88.6%) 75.7% 66.7% 81.8%
Specificity 54.0% (CI: 47.0–69.1%) 59.0% 50.8% 63.5%
AD, Alzheimer’s disease; MCI, mild cognitive impairment; MRAC, MR-based attenuation correction.
https://doi.org/10.1371/journal.pone.0233886.t001
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for each modality from different PET raw data [28]. Our goal was to evaluate the vendor-pro-
vided atlas AC, and to use the same PET raw data in the generation of error maps.
Moodley et al. enrolled 24 dementia patients [29]. However, the main focus of their study
was to evaluate the concordance between FDG-PET and MRI in dementia patients, rather
than the validation of MRAC compared with the gold standard: FDG-PET derived from
CTAC.
Further studies have been published on the validation of MRAC for brain FDG-PET, some
of which recruited AD patients [10, 30, 31]. However, the main focus of these studies was to
clarify the extent and distribution of error introduced by MRAC. None of these studies evalu-
ated the impact of these errors on the diagnostic accuracy for AD in an objective manner. In
addition, these studies were performed on different MR systems with different underlying
Fig 2. Accuracy, sensitivity and specificity in original ADNI data and each of the 47 datasets with simulated
MRAC error.Discrimination of Alzheimer’s disease (AD) patients from normal subjects (A) and the prediction of
mild cognitive impairment (MCI) progression to AD. 95% confidence intervals are shown as Whisker plots. All 47
datasets maintain their accuracy and specificity compared with the original data, while five out of 47 error datasets
slightly impaired the sensitivity for the discrimination of AD.
https://doi.org/10.1371/journal.pone.0233886.g002
Fig 3. Bland-Altman plots of best three cases (A) and worst three cases (B) for 203 simulated PET data with MRAC
error. The PET score tends to be underestimated, especially in the worst cases.
https://doi.org/10.1371/journal.pone.0233886.g003
PLOS ONE FDG-PET/MR for Alzheimer’s disease
PLOSONE | https://doi.org/10.1371/journal.pone.0233886 June 3, 2020 9 / 14
PET-technology, i.e. the Siemens mMR. There is evidence that the time-of-flight (TOF) capa-
bility of the GE SIGNA PET/MRmight compensate for errors introduced by MRAC [12].
We used a fully automated, commercially available, Alzheimer’s discrimination analysis to
calculate a predictive value for AD. The normal database of FDG PET images used for the dis-
crimination (calculation of t-value) in this tool were acquired on conventional PET/CT scan-
ners [15]. Based on our study alone, it is difficult to determine whether a PET/MR-specific
FDG-PET database should be constructed [27]. However, our finding that diagnostic accuracy
Fig 4. Representative case. The original PET images extracted from ADNI-cohort (A). After spatial and value normalization, the normalized images were acquired (B).
The voxel-wise differences between the expected and patient-specific images are used to calculate t-values (C). The original error map was obtained by dividing PET
based on Atlas-AC by that on CT-AC, followed by normalization identical to that used for the ADNI-PET data (D, F). We multiplied the normalized PET (B) with each
normalized error map (D and F), followed by calculation of the t-value map of the simulated PET (not shown in this figure). The error of the t-value maps was obtained
by subtracting the original t-value map from the simulated t-value map (E and G). More detailed figures are shown in S2 Fig.
https://doi.org/10.1371/journal.pone.0233886.g004
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was maintained between FDG-PET/MR with atlas-based MRAC and PET/CT indicates that
the database for FDG-PET/CT could be used for FDG-PET/MR.
A recent multi-center trial revealed that some novel MRAC methods could generate near
“gold standard” AC-maps fromMR data on PET/MR [30]. In addition, deep-learning-based
MRACmethods have been validated and provided prominent accuracy [32–34]. However,
implementation and adoption on commercially available systems will certainly vary among
vendors and users. At most institutions with a PET/MR scanner, researchers and physicians
can only choose between the MRAC provided by the vendor, a multi-atlas based method avail-
able via a web interface (http://cmictig.cs.ucl.ac.uk/niftyweb/program.php?p=PCT) or their
own reconstruction algorithm [12, 35].
There were a number of limitations in our study. First, the data acquisition in patients was
heterogeneous and not optimized in all cases for brain PET (short 2 min scan duration and
variable post-injection time). Using only 2 min acquisition for brain PET images could limit
image quality, despite the use of a state-of-the-art PET/MR scanner with high sensitivity detec-
tor [36]. To mitigate this, all images were smoothed with a Gaussian filter of 12 x 12 x 12 mm
which step has been included in PALZ as one of the analysis steps. In addition, we proved that
there was no significant difference of PET score error between short scan time (2min) cohort
at InA and relatively longer scan time (10min) cohort at InB. Second, brain PET data was
taken from patients imaged for oncologic staging, rather than dedicated brain imaging. How-
ever, the error introduced by MRAC primarily results from differences in skull bone detection
which is not expected to systematically vary among oncology and AD patients. Third, a limited
number of patients, n = 47, were used to generate MRAC error maps. This is substantially
smaller than a previous larger cohort study that validated the performance of MRAC (n = 337)
[30]. In addition, the dataset evaluated in the current study consisted entirely of simulated
images which combined PET data on different scanners. In future studies a larger dataset of
real patient images should be assessed. Fourth, we chose not to focus on the diagnosis of other
types of dementia; e.g. fronto-temporal lobar degeneration, dementia with Lewy bodies and
vascular dementia, which is sometimes difficult to distinguish from AD in a clinical setting.
Fifth, the outcome measure was derived from a single software tool, and visual assessment by
an experienced reader was not included. However, the main focus of this study was not on the
tool itself but to assess the diagnostic accuracy of FDG PET from PET/MR with vendor-pro-
vided atlas AC for AD, in a controlled manner. This goal was fulfilled by the current study,
because the diagnostic concept is similar between software or visual assessment. Sixth, we only
evaluated a single atlas-based MRACmethod. Cross validation using several MRACmethods,
provided by other vendors or researchers, should be performed in the future.
Conclusion
FDG-PET/MR based on atlas-based MR attenuation showed similar diagnostic accuracy than
the CT-based method for the diagnosis of Alzheimer’s disease and the prediction of the pro-
gression of mild cognitive impairment to Alzheimer’s disease using the PMOD-based PALZ
software, although with a minor reduction in sensitivity.
Supporting information
S1 Fig. Overview of the automated Alzheimer’s discrimination software (PMOD PALZ)
algorithm. A detailed description is provided in the materials and methods section.
(TIF)
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S2 Fig. The original PET images extracted from ADNI-cohort (A) were spatially normalized
to the SPM99 PET template, followed by smoothing with a Gaussian filter of 12 x 12 x 12 mm.
Secondly, voxel values were normalized by dividing each image voxel value by the mean voxel
value, averaged within a mask representing voxels with AD-preserved activity (B). The voxel-
wise differences between the expected and patient-specific images are used to calculate t-values
(C). The error map was obtained by dividing PET based on Atlas-AC by that on CT-AC, fol-
lowed by the normalization to the identical space as spatially normalized ADNI-PET data. The
original error map is shown in figures (D) and (F). We multiplied the normalized PET (B)
with each normalized error map (D and F), followed by calculation of the t-value map of the
simulated PET (not shown in this figure). The error of the t-value maps was obtained by sub-
tracting the original t-value map from the simulated t-value map (E and G). The yellow VOI
corresponds to AD-related voxels. The original PET-score of ADNI-data was 0.9385. The
PET-score of simulated data was 1.0478 for pt-11 and 0.9497 for pt-14. More detailed figures
are shown in S2 Fig.
(JPG)
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10. Sgard B, Khalifé M, Bouchut A, et al. ZTEMR-based attenuation correction in brain FDG-PET/MR: per-
formance in patients with cognitive impairment. Eur Radiol. 2020; 30:1770–1779.
11. Andersen FL, Ladefoged CN, Beyer T, et al. Combined PET/MR imaging in neurology: MR-based atten-
uation correction implies a strong spatial bias when ignoring bone.Neuroimage. 2014; 84:206–216.
https://doi.org/10.1016/j.neuroimage.2013.08.042 PMID: 23994317
12. Sekine T, Burgos N, Warnock G, et al. Multi-Atlas-Based Attenuation Correction for Brain 18F-FDG
PET Imaging Using a Time-of-Flight PET/MR Scanner: Comparison with Clinical Single-Atlas- and CT-
Based Attenuation Correction. J Nucl Med. 2016; 57:1258–1264. https://doi.org/10.2967/jnumed.115.
169045 PMID: 27013697
13. Sekine T, Buck A, Delso G, et al. Evaluation of Atlas-Based Attenuation Correction for Integrated PET/
MR in Human Brain: Application of a Head Atlas and Comparison to True CT-Based Attenuation Cor-
rection. J Nucl Med. 2016; 57:215–220. https://doi.org/10.2967/jnumed.115.159228 PMID: 26493207
14. Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated (18)F-FDG PET score as a bio-
marker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2011;
52:1218–1226. https://doi.org/10.2967/jnumed.111.090902 PMID: 21764801
15. Haense C, Herholz K, Jagust WJ, HeissWD. Performance of FDG PET for detection of Alzheimer’s dis-
ease in two independent multicentre samples (NEST-DD and ADNI).Dement Geriatr Cogn Disord.
2009; 28:259–266. https://doi.org/10.1159/000241879 PMID: 19786778
PLOS ONE FDG-PET/MR for Alzheimer’s disease
PLOSONE | https://doi.org/10.1371/journal.pone.0233886 June 3, 2020 13 / 14
16. Sekine T, Ter Voert EE,Warnock G, et al. Clinical Evaluation of Zero-Echo-Time Attenuation Correction
for Brain 18F-FDG PET/MRI: Comparison with Atlas Attenuation Correction. J Nucl Med. 2016;
57:1927–1932. https://doi.org/10.2967/jnumed.116.175398 PMID: 27339875
17. Delso G, Kemp B, Kaushik S, Wiesinger F, Sekine T. Improving PET/MR brain quantitation with tem-
plate-enhanced ZTE.Neuroimage. 2018; 181:403–413. https://doi.org/10.1016/j.neuroimage.2018.07.
029 PMID: 30010010
18. Wollenweber SD, Ambwani S, Delso G, et al. Evaluation of an atlas-based PET head attenuation cor-
rection using PET/CT &MR patient data. IEEE Trans Nucl Sci. 2013; 60:3383–3390.
19. Ito K, Fukuyama H, SendaM, et al. Prediction of Outcomes in Mild Cognitive Impairment by Using 18F-
FDG-PET: A Multicenter Study. J Alzheimers Dis. 2015; 45:543–552. https://doi.org/10.3233/JAD-
141338 PMID: 25589723
20. Inui Y, Ito K, Kato T, Group S-JS. Longer-Term Investigation of the Value of 18F-FDG-PET and Mag-
netic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer’s
Disease: A Multicenter Study. J Alzheimers Dis. 2017; 60:877–887. https://doi.org/10.3233/JAD-
170395 PMID: 28922157
21. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by auto-
mated analysis of multicenter FDG PET.Neuroimage. 2002; 17:302–316. https://doi.org/10.1006/nimg.
2002.1208 PMID: 12482085
22. Friston KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowiak RSJ. Spatial registration and nor-
malization of images.Hum Brain Mapp. 1995; 3:165–189.
23. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps
in functional imaging: A general linear approach.HumBrain Mapp. 1994; 2:189–210.
24. Steel RGD, Torrie JH. Principles and procedures of statistics, a biometrical approach: McGraw-Hill
Kogakusha, Ltd.; 1980.
25. YoudenWJ. Index for rating diagnostic tests.Cancer. 1950; 3:32–35. https://doi.org/10.1002/1097-
0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 PMID: 15405679
26. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Journal
of the Royal Statistical Society: Series D (The Statistician). 1983; 32:307–317.
27. Hitz S, Habekost C, Furst S, et al. Systematic Comparison of the Performance of IntegratedWhole-
Body PET/MR Imaging to Conventional PET/CT for (1)(8)F-FDGBrain Imaging in Patients Examined
for Suspected Dementia. J Nucl Med. 2014; 55:923–931. https://doi.org/10.2967/jnumed.113.126813
PMID: 24833495
28. Bailey DL, Pichler BJ, Guckel B, et al. Combined PET/MRI: Global Warming-Summary Report of the
6th International Workshop on PET/MRI, March 27–29, 2017, Tubingen, Germany.Mol Imaging Biol.
2018; 20:4–20. https://doi.org/10.1007/s11307-017-1123-5 PMID: 28971346
29. Moodley KK, Perani D, Minati L, et al. Simultaneous PET-MRI Studies of the Concordance of Atrophy
and Hypometabolism in Syndromic Variants of Alzheimer’s Disease and Frontotemporal Dementia: An
Extended Case Series. J Alzheimers Dis. 2015; 46:639–653. https://doi.org/10.3233/JAD-150151
PMID: 26402512
30. Ladefoged CN, Law I, Anazodo U, et al. A multi-centre evaluation of eleven clinically feasible brain PET/
MRI attenuation correction techniques using a large cohort of patients.Neuroimage. 2017; 147:346–
359. https://doi.org/10.1016/j.neuroimage.2016.12.010 PMID: 27988322
31. Cabello J, Lukas M, Rota Kops E, et al. Comparison betweenMRI-based attenuation correction meth-
ods for brain PET in dementia patients. Eur J Nucl Med Mol Imaging. 2016.
32. Shiri I, Ghafarian P, Geramifar P, et al. Direct attenuation correction of brain PET images using only
emission data via a deep convolutional encoder-decoder (Deep-DAC). Eur Radiol. 2019; 29:6867–
6879. https://doi.org/10.1007/s00330-019-06229-1 PMID: 31227879
33. Arabi H, Zeng G, Zheng G, Zaidi H. Novel adversarial semantic structure deep learning for MRI-guided
attenuation correction in brain PET/MRI. Eur J Nucl Med Mol Imaging. 2019; 46:2746–2759. https://doi.
org/10.1007/s00259-019-04380-x PMID: 31264170
34. Liu F, Jang H, Kijowski R, Bradshaw T, McMillan AB. Deep Learning MR Imaging-based Attenuation
Correction for PET/MR Imaging.Radiology. 2018; 286:676–684. https://doi.org/10.1148/radiol.
2017170700 PMID: 28925823
35. Burgos N, CardosoMJ, Thielemans K, et al. Multi-contrast attenuation map synthesis for PET/MR scan-
ners: assessment on FDG and Florbetapir PET tracers. Eur J Nucl MedMol Imaging. 2015; 42:1447–
1458. https://doi.org/10.1007/s00259-015-3082-x PMID: 26105119
36. Sekine T, Delso G, Zeimpekis KG, et al. Reduction of (18)F-FDG Dose in Clinical PET/MR Imaging by
Using Silicon Photomultiplier Detectors.Radiology. 2018; 286:249–259. https://doi.org/10.1148/radiol.
2017162305 PMID: 28914600
PLOS ONE FDG-PET/MR for Alzheimer’s disease
PLOSONE | https://doi.org/10.1371/journal.pone.0233886 June 3, 2020 14 / 14
